PL374833A1 - 5-aryltetrazole compounds, compositions thereof, and uses therefor - Google Patents

5-aryltetrazole compounds, compositions thereof, and uses therefor

Info

Publication number
PL374833A1
PL374833A1 PL03374833A PL37483303A PL374833A1 PL 374833 A1 PL374833 A1 PL 374833A1 PL 03374833 A PL03374833 A PL 03374833A PL 37483303 A PL37483303 A PL 37483303A PL 374833 A1 PL374833 A1 PL 374833A1
Authority
PL
Poland
Prior art keywords
compositions
uses therefor
aryltetrazole compounds
aryltetrazole
compounds
Prior art date
Application number
PL03374833A
Other languages
Polish (pl)
Inventor
Alex Nivorozhkin
Duzer John Van
Andrew Salzman
Garry Southan
Siya Ram
Qi Zeng
Csaba Szabo
Original Assignee
Inotek Pharmaceuticals Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corporation filed Critical Inotek Pharmaceuticals Corporation
Publication of PL374833A1 publication Critical patent/PL374833A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03374833A 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof, and uses therefor PL374833A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/197,609 US7078423B2 (en) 2002-07-18 2002-07-18 5-Aryltetrazole compounds, compositions thereof, and uses therefor

Publications (1)

Publication Number Publication Date
PL374833A1 true PL374833A1 (en) 2005-10-31

Family

ID=30769479

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374833A PL374833A1 (en) 2002-07-18 2003-07-17 5-aryltetrazole compounds, compositions thereof, and uses therefor

Country Status (16)

Country Link
US (1) US7078423B2 (en)
EP (1) EP1542980A1 (en)
JP (1) JP2005535678A (en)
KR (1) KR20050028038A (en)
CN (1) CN1694875A (en)
AU (1) AU2003249313A1 (en)
BR (1) BR0312768A (en)
CA (1) CA2492847A1 (en)
HU (1) HUP0500871A3 (en)
IL (1) IL166331A0 (en)
MX (1) MXPA05000765A (en)
NZ (1) NZ538313A (en)
PL (1) PL374833A1 (en)
RU (1) RU2005104429A (en)
WO (1) WO2004009563A1 (en)
ZA (1) ZA200501431B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
PA8578101A1 (en) * 2002-08-13 2004-05-07 Warner Lambert Co HETEROBIARILO DERIVATIVES AS METALOPROTEINASE IN MATRIX INHIBITORS
US7037927B2 (en) 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2607953A1 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
ES2604542T3 (en) * 2006-06-29 2017-03-07 F. Hoffmann-La Roche Ag Tetrazol substituted arylamides
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A Methods for preserving renal function using xanthine oxidoreductase inhibitors
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
CN101679244B (en) * 2007-04-11 2014-01-01 橘生药品工业株式会社 5-membered heterocyclic derivative and use thereof for medical purposes
ES2443290T3 (en) * 2007-10-04 2014-02-18 F. Hoffmann-La Roche Ag Tetrazol substituted arylamide derivatives and uses thereof
MX2010011603A (en) * 2008-04-30 2011-01-25 Wellstat Therapeutics Corp Tetrazole compounds for reducing uric acid.
WO2011035332A1 (en) 2009-09-21 2011-03-24 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r ( chemr23 ) modulators
JP5806221B2 (en) 2009-10-13 2015-11-10 ウェルスタット セラピューティクス コーポレイション 3-Substituted compounds that reduce uric acid
US9918964B2 (en) * 2010-04-23 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Reducing platelet activation, aggregation and platelet-stimulated thrombosis or blood coagulation by reducing mitochondrial respiration
ES2532210T3 (en) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Methods for the concomitant treatment of theophylline and febuxostat
WO2014079850A1 (en) * 2012-11-23 2014-05-30 F. Hoffmann-La Roche Ag Substituted heterocyclic derivatives
WO2016187521A1 (en) * 2015-05-21 2016-11-24 South Connecticut State University 5-substituted 1 h-tetrazole compounds, methods of synthesizing and therapeutic use
US20210061800A1 (en) * 2017-12-29 2021-03-04 Agency For Science, Technology And Research Compounds for treating eye diseases and methods thereof
KR20220054286A (en) * 2019-06-25 2022-05-02 시놉세 테라페우틱스 Compounds for the treatment of eye disorders
CN112047896B (en) * 2020-10-12 2022-06-17 上海麦克林生化科技有限公司 Method for synthesizing aromatic ring group or aromatic heterocyclic group tetrazole
CN114805233A (en) * 2022-03-30 2022-07-29 华南理工大学 Phenyl tetrazole type XOR inhibitor and preparation method and application thereof
CN115717258B (en) * 2022-12-09 2024-11-15 上海天承化学有限公司 Leveling agent for pulse hole filling electroplating of printed circuit board and application thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049572A (en) * 1987-04-06 1991-09-17 Riker Laboratories, Inc. Substituted di-t-butylphenols and anti-allergic use thereof
IT1232252B (en) * 1989-02-22 1992-01-28 Rotta Research Lab DERIVATIVES OF N N PHENYL BENZAMIDE WITH ANTI-ULTER AND ANTIALLERIC ACTIVITY AND PROCEDURE FOR THEIR PREPARATION
US5284954A (en) * 1990-09-10 1994-02-08 Abbott Laboratories Process for the preparation of tetrazoles
IT1256870B (en) 1992-02-13 1995-12-27 Rotta Research Lab BIS-TETRAZOLE DERIVATIVES WITH ANTIALLERGIC AND CYTOPROTECTIVE ACTIVITY
US5364869A (en) * 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
DE4326344A1 (en) 1993-08-05 1995-02-09 Thomae Gmbh Dr K Carbonamides, pharmaceutical compositions containing these compounds and process for their preparation
US5874593A (en) * 1994-05-16 1999-02-23 Sumitomo Chemical Company, Limited Production process and intermediate of tetrazole compound
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
JPH1025294A (en) 1996-03-26 1998-01-27 Akira Matsuda Fused heterocyclic derivative, method for producing the same, and therapeutic agent for malignant tumor containing the same
JP4073489B2 (en) * 1996-05-24 2008-04-09 ニューロサーチ・アクティーゼルスカブ PHENYL DERIVATIVE HAVING ACID GROUP, PROCESS FOR PRODUCING THE SAME, AND METHOD FOR USING THE SAME AS CHLORIDE CHANNEL BLOCKING AGENT
US6696475B2 (en) * 1997-04-22 2004-02-24 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
CN1118462C (en) * 1997-04-22 2003-08-20 神经研究公司 Substituted phenyl derivatives, their preparation and use
EP0990369B1 (en) 1997-06-19 2003-07-09 BRITISH TELECOMMUNICATIONS public limited company Sound reproduction system
DE69722610T2 (en) * 1997-08-08 2004-04-29 Rotta Research Laboratorium S.P.A., Monza New inhalation preparations containing CR 2039 (Andolast)
WO1999024038A1 (en) 1997-11-07 1999-05-20 Johns Hopkins University Methods for treatment of disorders of cardiac contractility
AU1457299A (en) 1997-11-12 1999-05-31 Ariad Pharmaceuticals, Inc. Novel signal transduction inhibitors, compositions containing them
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
SK5222001A3 (en) * 1998-10-22 2002-05-09 Neurosearch As Substituted phenyl derivatives, their preparation and use
DK1283036T3 (en) 1998-11-13 2008-03-25 Jagotec Ag Dry powder for inhalation
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US6281222B1 (en) * 1999-08-19 2001-08-28 Inotek Corporation Compositions and method for treatment of acetaminophen intoxication
IL151517A0 (en) 2000-03-09 2003-04-10 Aventis Pharma Gmbh Therapeutic uses of ppar mediators
DE10023430A1 (en) 2000-05-12 2001-11-15 Bayer Ag New N-benzoyl-N'-(tetrazolyl-phenyl)-urea derivatives, useful as pesticides e.g. insecticides, acaricides, nematocides, ectoparasiticides, antifouling agents, herbicides, fungicides and bactericides
WO2002000647A1 (en) 2000-06-23 2002-01-03 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
MXPA04002404A (en) * 2001-09-14 2004-05-31 Novo Nordisk As NOVEL LIGANDS FOR THE HisB10 Zn2+.

Also Published As

Publication number Publication date
KR20050028038A (en) 2005-03-21
WO2004009563A1 (en) 2004-01-29
NZ538313A (en) 2005-09-30
US20040019208A1 (en) 2004-01-29
ZA200501431B (en) 2006-02-22
CA2492847A1 (en) 2004-01-29
US7078423B2 (en) 2006-07-18
HUP0500871A2 (en) 2005-12-28
MXPA05000765A (en) 2005-10-19
BR0312768A (en) 2005-05-10
EP1542980A1 (en) 2005-06-22
HUP0500871A3 (en) 2006-11-28
JP2005535678A (en) 2005-11-24
CN1694875A (en) 2005-11-09
AU2003249313A1 (en) 2004-02-09
IL166331A0 (en) 2006-01-16
RU2005104429A (en) 2005-08-27

Similar Documents

Publication Publication Date Title
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) Compounds, methods and compositions
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
EP1542699A4 (en) Compounds, compositions, and methods employing same
AU2003270015A8 (en) Compounds, compositions, and methods
GB0213638D0 (en) Composition
AU2003299612A8 (en) Compounds, compositions and methods
IL164581A0 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
ZA200501431B (en) 5-Aryltetrazole compounds, compositions thereof, and uses therefor.
GB0203421D0 (en) Composition
AU2003290507A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
GB0203280D0 (en) Anti-glycolytic composition
GB0208608D0 (en) Composition
GB0307695D0 (en) Compounds,compositions and processes
GB0322041D0 (en) Cast-cutter
GB0211924D0 (en) Composition
AU2003300031A8 (en) Compounds, compositions, and methods
AU2003267169A8 (en) Compounds, compositions and methods
EP1495751A4 (en) Hairdye composition
GB0213767D0 (en) Composition
GB0203357D0 (en) Compounds,compositions and uses
GB0203616D0 (en) Composition

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)